Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
PLoS One
2018 May 15;135:e0197634. doi: 10.1371/journal.pone.0197634.
Show Gene links
Show Anatomy links
Binding of sulphonylureas to plasma proteins - A KATP channel perspective.
Proks P
,
Kramer H
,
Haythorne E
,
Ashcroft FM
.
???displayArticle.abstract???
Sulphonylurea drugs stimulate insulin secretion from pancreatic β-cells primarily by inhibiting ATP sensitive potassium (KATP) channels in the β-cell membrane. The effective sulphonylurea concentration at its site of action is significantly attenuated by binding to serum albumin, which makes it difficult to compare in vitro and in vivo data. We therefore measured the ability of gliclazide and glibenclamide to inhibit KATP channels and stimulate insulin secretion in the presence of serum albumin. We used this data, together with estimates of free drug concentrations from binding studies, to predict the extent of sulphonylurea inhibition of KATP channels at therapeutic concentrations in vivo. KATP currents from mouse pancreatic β-cells and Xenopus oocytes were measured using the patch-clamp technique. Gliclazide and glibenclamide binding to human plasma were determined in spiked plasma samples using an ultrafiltration-mass spectrometry approach. Bovine serum albumin (60g/l) produced a mild, non-significant reduction of gliclazide block of KATP currents in pancreatic β-cells and Xenopus oocytes. In contrast, glibenclamide inhibition of recombinant KATP channels was dramatically suppressed by albumin (predicted free drug concentration <0.1%). Insulin secretion was also reduced. Free concentrations of gliclazide and glibenclamide in the presence of human plasma measured in binding experiments were 15% and 0.05%, respectively. Our data suggest the free concentration of glibenclamide in plasma is too low to account for the drug's therapeutic effect. In contrast, the free gliclazide concentration in plasma is high enough to close KATP channels and stimulate insulin secretion.
???displayArticle.pubmedLink???
29772022
???displayArticle.pmcLink???PMC5957440 ???displayArticle.link???PLoS One ???displayArticle.grants???[+]
Fig 1. Effect of BSA on gliclazide block of the β-cell KATP current. (A,B) Representative whole-cell KATP currents
recorded from mouse pancreatic β-cells in response to alternating ±20mV steps from a holding potential of -70mV.
Gliclazide (1μmol/l) was added (as indicated by the bars) in the absence (A) or presence (B) of 0.9mmol/l BSA. The
dotted line indicates the zero current level. (C) Concentration-response relationships for gliclazide inhibition of wholecell
KATP currents in mouse β-cells in the absence (, n = 6) or presence (●, n = 5) of 0.9mmol/l BSA. Current is
expressed relative to that in the absence of gliclazide. The solid lines are the best fit of Eq 2 to the mean data: () IC50 =190nmol/l, h = 0.97, a = 0.05; (●) IC50 = 320nmol/l, h = 0.90, a = 0.03. This shift predicts 60% of drug is bound and a
dissociation constant (Kd) for drug binding to BSA of ~1.3mmol/l (Eq 3). The dotted line is the estimated gliclazide
block in the presence of human plasma (HP) assuming gliclazide binds to plasma proteins with a Kd of 155μmol/l. The
width of the grey bar indicates the mean CSS±SEM (steady-state total plasma concentrations of sulphonylurea drugs) of
the total gliclazide concentration in the plasma estimated from a daily dose of 80mg and an AUC (the area under the
plasma concentration against time curve) of 44μg.h/ml [26].
Fig 2. Effect of BSA on glibenclamide and gliclazide block of recombinant β-cell KATP channels. (A,B) Representative Kir6.2/SUR1 currents recorded at -60mV from
cell-attached patches on Xenopus oocytes. Currents were recorded in the presence of 3mmol/l Na-azide (top trace), 3mmol/l Na-azide plus 1μmol/l glibenclamide (A,
middle) or 3mmol/l Na-azide plus 1μmol/l gliclazide (B, middle), and 3mmol/l Na-azide, 1μmol/l glibenclamide and 0.9mmol/l BSA (A, bottom) or 3mmol/l Na-azide,
1μmol/l gliclazide and 0.9mmol/l BSA (C, bottom). The dotted line indicates the zero current level. (C) Concentration-response relationships for glibenclamide inhibition
of Kir6.2/SUR1 currents in the absence (, n = 10) and presence (●, n = 10) of 0.9mmol/l BSA. Open probability (PO) was recorded in the cell-attached configuration and
is expressed relative to that in the absence of glibenclamide. The lines are the best fit of Eq 2 to the mean data: () IC50 = 1.2nmol/l, h = 1.1; (●) IC50 = 1.6μmol/l, h = 0.95.
a was set at 0 in both cases. The dotted line is the estimated glibenclamide block in the presence of human plasma (HP) assuming the drug binds to plasma proteins with a
Kd of 0.44μmol/l. The width of the grey bar indicates the mean CSS±SEM of the total glibenclamide concentration in the plasma of patients with type 2 diabetes [28]. (D)
Concentration-response relationships for gliclazide inhibition of Kir6.2/SUR1 currents in the absence (, n = 10) and presence (●, n = 10) of 0.9mmol/l BSA. Open
probability (PO) was recorded in the cell-attached configuration and is expressed relative to that in the absence of gliclazide. The lines are the best fit of Eq 2 to the mean
data: IC50 = 128nmol/l, h = 1.3 (); IC50 = 217nmol/l, h = 1.3 (●). a was set at 0. The IC50 obtained in the absence of BSA (128nmol/l) is similar to that previously reported
for whole-cell Kir6.2/SUR1 currents in oocytes (108nmol/l; [27]). The width of the grey bar indicates the mean CSS±SEM of the total gliclazide concentration in the
plasma estimated from a daily dose of 80mg and an AUC of 44μg.h/ml [26].
Fig 3. Effect of BSA on glibenclamide stimulated insulin release. Insulin secretion was evaluated in islets from 8–10 week-old male mice in response to 60–120
minute stimulation with various glucose and glibenclamide concentrations, as indicated, in the presence of (A) 15μmol/l BSA or (B) 0.9mmol/l BSA (n = 3 animals, 3
technical replicates per condition). Insulin secretion is expressed as a percentage of the insulin content. Insulin secretion in the presence of glucose and glibenclamide
was significantly affected by the BSA concentration (F(5,12) = 10.77; p = 0.004). For both incubation times and for all drug concentrations tested, insulin secretion was
significantly lower in the presence of 0.9mmol/l BSA than 15μM BSA (p<0.05).
Fig 4. Glucose and glibenclamide block of the KATP channel. (A) Concentration-response relationships for glucose
inhibition of KATP conductance in pancreatic β-cells from wild-type (, n = 5) and βV59M (●, n = 8) mice, measured
using the perforated patch configuration. Data are the same as those in [16] but are replotted as nS/pF. (B)
Concentration-response relationships for glibenclamide inhibition of KATP conductance in pancreatic β-cells from
wild-type (, n = 6) and βV59M (●, n = 6) mice, measured using the perforated patch configuration. Data are the same
as those in [18] but are replotted as nS/pF. Note the ‘pedestal’ (arrowed) in the dose-response curve for glibenclamide
inhibition. This results because glibenclamide binds to SUR1 with high affinity and acts a partial antagonist of the
KATP channel, with a maximal block of ~60–80% [14]. It also produces a low affinity block at Kir6.2. However, like
other sulphonylureas [39], glibenclamide also displaces MgADP from NBD2 of SUR1, which prevents MgADP
activation and thereby reveals the full extent of ATP block at Kir6.2. Thus, in the presence of intracellular nucleotides,
inhibition is the sum of the high-affinity glibenclamide block at SUR1, ATP block at Kir6.2, and a low-affinity block by
glibenclamide at Kir6.2.
Abdelmoneim,
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
2012, Pubmed
Abdelmoneim,
Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
2012,
Pubmed
Ammälä,
Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels.
1996,
Pubmed
,
Xenbase
Anello,
Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients.
2005,
Pubmed
Anguizola,
Review: Glycation of human serum albumin.
2013,
Pubmed
Ashcroft,
Electrophysiology of the pancreatic beta-cell.
1989,
Pubmed
Brereton,
Reversible changes in pancreatic islet structure and function produced by elevated blood glucose.
2014,
Pubmed
Carpentier,
Internalization of 3H-glibenclamide in pancreatic islet cells.
1986,
Pubmed
Doliba,
Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics.
2012,
Pubmed
Ferrer,
Effects of Zn2+ on glucose-induced electrical activity and insulin release from mouse pancreatic islets.
1984,
Pubmed
Girard,
Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes.
2009,
Pubmed
Gomis,
Oscillatory patterns of electrical activity in mouse pancreatic islets of Langerhans recorded in vivo.
1996,
Pubmed
Gopalakrishnan,
Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells.
2000,
Pubmed
Gribble,
Sulphonylurea action revisited: the post-cloning era.
2003,
Pubmed
Gribble,
Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.
1998,
Pubmed
,
Xenbase
Gribble,
The interaction of nucleotides with the tolbutamide block of cloned ATP-sensitive K+ channel currents expressed in Xenopus oocytes: a reinterpretation.
1997,
Pubmed
,
Xenbase
Göpel,
Regulation of glucagon release in mouse -cells by KATP channels and inactivation of TTX-sensitive Na+ channels.
2000,
Pubmed
Göpel,
Patch-clamp characterisation of somatostatin-secreting -cells in intact mouse pancreatic islets.
2000,
Pubmed
Hellman,
Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets.
1984,
Pubmed
Hellman,
Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells.
1974,
Pubmed
Henquin,
Nutrient control of insulin secretion in isolated normal human islets.
2006,
Pubmed
Hsu,
Interactions of sulfonylureas with plasma proteins.
1974,
Pubmed
Kobayashi,
Influence of blood proteins on biomedical analysis. IX. Protective effects of human serum proteins on anion-induced degradation of gliclazide.
1986,
Pubmed
Kwong,
Free drug measurements: methodology and clinical significance.
1985,
Pubmed
Lahmann,
Systemic Administration of Glibenclamide Fails to Achieve Therapeutic Levels in the Brain and Cerebrospinal Fluid of Rodents.
2015,
Pubmed
Lawrence,
Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells.
2001,
Pubmed
Martin,
Anti-diabetic drug binding site in a mammalian KATP channel revealed by Cryo-EM.
2017,
Pubmed
Matsuda,
Analysis of drug interactions with modified proteins by high-performance affinity chromatography: binding of glibenclamide to normal and glycated human serum albumin.
2012,
Pubmed
Matsuda,
High-performance affinity chromatography and the analysis of drug interactions with modified proteins: binding of gliclazide with glycated human serum albumin.
2011,
Pubmed
McCulloch,
GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: implications for understanding genetic association signals at this locus.
2011,
Pubmed
Myngheer,
Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes.
2014,
Pubmed
Olsen,
Glyburide protein binding and the effect of albumin glycation in children, young adults, and older adults with diabetes.
1995,
Pubmed
Park,
Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide.
2003,
Pubmed
Pearson,
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
2006,
Pubmed
,
Xenbase
Pertusa,
Zn2+ chelation by serum albumin improves hexameric Zn2+-insulin dissociation into monomers after exocytosis.
2017,
Pubmed
Proks,
Molecular mechanism of sulphonylurea block of K(ATP) channels carrying mutations that impair ATP inhibition and cause neonatal diabetes.
2013,
Pubmed
,
Xenbase
Proks,
Functional effects of KCNJ11 mutations causing neonatal diabetes: enhanced activation by MgATP.
2005,
Pubmed
,
Xenbase
Proks,
Activation of the K(ATP) channel by Mg-nucleotide interaction with SUR1.
2010,
Pubmed
,
Xenbase
Proks,
Sulfonylurea stimulation of insulin secretion.
2002,
Pubmed
Renström,
Sulfonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive K+ channel-independent action.
2002,
Pubmed
Russ,
Incomplete dissociation of glibenclamide from wild-type and mutant pancreatic K ATP channels limits their recovery from inhibition.
2009,
Pubmed
Rydberg,
Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans.
1994,
Pubmed
Sartor,
Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide.
1980,
Pubmed
Schwanstecher,
Location of the sulphonylurea receptor at the cytoplasmic face of the beta-cell membrane.
1994,
Pubmed
Schwanstecher,
Phosphate and thiophosphate group donating adenine and guanine nucleotides inhibit glibenclamide binding to membranes from pancreatic islets.
1991,
Pubmed
Seedher,
Reversible binding of antidiabetic drugs, repaglinide and gliclazide, with human serum albumin.
2008,
Pubmed
Seibert,
Factors influencing nominal effective concentrations of chemical compounds in vitro: medium protein concentration.
2002,
Pubmed
Smith,
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.
2010,
Pubmed
Tsuchiya,
Nonenzymatic glucosylation of human serum albumin and its influence on binding capacity of sulfonylureas.
1984,
Pubmed
Zhang,
The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs.
2009,
Pubmed
Zünkler,
Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K+ currents in pancreatic B-cells.
1988,
Pubmed